{"title":"Therapeutic use of autologous hematopoietic bone marrow transplant combined with concentrated platelet in infected surgical wounds: single-center prospective study","authors":"nasser Yousif","doi":"10.18081/2333-5106/2024.12/52","DOIUrl":"https://doi.org/10.18081/2333-5106/2024.12/52","url":null,"abstract":"The healing wound is the consecutive process of maintaining tissue integrity including inflammatory, proliferative, and remodeling processes. Stem cells can self-renew, and also to differentiate into all cell types, and are involved in physiological regeneration, use of mesenchymal stem cells deriving from the bone marrow with PRP has potentiated the healing process. We conducted a single-arm pilot prospective analytical study was performed on 15 patients whose mean age was 31 years (range: 29–51 years), with refractory abdominal wounds at a private hospital in Iraq from March 30, 2022, to March 2023. Ten days after the stem cell transplant the re-enforcement with PRP subcutaneous injection around wounds. Small papules of granulation tissue appeared over the wound, and tissue granulation increased from 80% (30.26–80.00%) to 100% (81–100%). At the same time, the wound size was reduced by 60% (52.10–78.23%). The follow-up period was 7–24 months, during which no recurrence of the wound was found. In conclusion, the current study is the first to characterize the safety and efficacy of bone marrow-derived stem cells in combination with PRP in the treatment of refractory abdominal wound infection. All patients achieved a 100% healing rate in a short time, and no treatment-related adverse reactions occurred during the treatment.","PeriodicalId":486374,"journal":{"name":"American journal of biomedicine","volume":"69 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fathur Budiyono, Achmad Firman, Ray Setiati, Erika Rah
{"title":"Investigates the genetic types of acute lymphoblastic leukemia in full remission Indonesian patients: a cross-sectional analysis","authors":"Fathur Budiyono, Achmad Firman, Ray Setiati, Erika Rah","doi":"10.18081/2333-5106/2024.12/43","DOIUrl":"https://doi.org/10.18081/2333-5106/2024.12/43","url":null,"abstract":"Acute lymphoblastic leukemia (ALL) is most common in children, especially those aged 1–4 years old, and the second most common acute leukemia in adults. The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes recent clinical, cytogenetic, and molecular data. Transcriptome sequencing (RNA-seq) was performed on 200 bone marrow specimens using TruSeq library preparation and HiSeq 2000/2500 or NovaSeq 6000 sequencers (Illumina). The purpose of this study was to define the frequency of chromosomal abnormalities of ALL patients in adults and children in Indonesian patients after full remission for international collaboration has improved and advanced the diagnosis and treatment of ALL in Indonesia. Our resulting data showed that the most common structural abnormality was t(9;22) in 15% of the patients. The frequency of genetic abnormalities was 69 % and 60% for numerical and/or structural in the B-ALL and T-ALL patients, respectively. The adults had a higher incidence of t(9;22) and a lower incidence of hyperdiploid than children. In conclusion: The results of this study molecular subtypes differ strikingly in their responses to treatment that needs more assessment.","PeriodicalId":486374,"journal":{"name":"American journal of biomedicine","volume":"9 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140713885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sreejith Prinja, Yashika Vanak, Pierre Rajsekar, Christl Singh
{"title":"Outcome of COVID-19 in patients with a history of acute leukemia; A Narrative Review","authors":"Sreejith Prinja, Yashika Vanak, Pierre Rajsekar, Christl Singh","doi":"10.18081/2333-5106/2024.12/33","DOIUrl":"https://doi.org/10.18081/2333-5106/2024.12/33","url":null,"abstract":"The chemotherapy and immunosuppressive medication may be associated with the suppressed immune system of a cancer patient making them susceptible to Coronavirus disease 2019 (COVID-19) with unclear mechanisms. We reviewed current studies on the clinical courses of leukemia patients with a risk of SARS-CoV-2 infection through searches in Pubmed databases and Google search engines. The criterion used for review includes their relevance to the defined review question, which is the outcome of COVID‐19 among leukemic patients and the relevant therapeutic interventions therewith. Patients with acute leukemia are among the most vulnerable groups of patients at risk of severe COVID-19 outcomes with several protocol management modifications proposed. The development of COVID-19 vaccines was an important milestone in reducing the risk of contracting and developing severe COVID-19 symptoms in leukemic patients after remission status. The European Society for Blood and Marrow Transplantation (EBMT), a collaborative network of centers and individuals working in the field of BMT and cellular therapy, has been updating its recommendations since the start of the COVID-19 pandemic.","PeriodicalId":486374,"journal":{"name":"American journal of biomedicine","volume":"27 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140734309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Sharma, H. Mishra, S. Singh, K. Longkumer, M. Dhuria
{"title":"CDKN1A down-regulation of inflammasomes and pro-inflammatory cytokines in pyroptosis of cartilage cells","authors":"M. Sharma, H. Mishra, S. Singh, K. Longkumer, M. Dhuria","doi":"10.18081/2333-5106/2024.12/11","DOIUrl":"https://doi.org/10.18081/2333-5106/2024.12/11","url":null,"abstract":"Osteoarthritis is the most common chronic degenerative disease worldwide; it mainly affects elderly people. This disease can involve nearly any joint in the human body, and the most common symptoms include joint pain and disordered articular functions. Inflammasomes (NLRP3) which are induced by nuclear factor kappa B (NF-κB) signaling and can convert interleukin-1β (IL-1β) and IL-18 into mature proinflammatory cytokines are considered a factor in low-grade inflammatory pathology. This study aimed to explore the mechanisms underlying CDKN1A-in osteoarthritis. Chondrocytes were collected and isolated from 22 patients with osteoarthritis (average age 50.22 ± 2.15) and healthy volunteers (average age 51.12 ± 2.34) were enrolled as the control group from June 2021 to June 2023. mRNA expression levels of CDKN1A, NLRP3, and cleaved-Caspase1) were detected by real-time PCR. Cell activity was calculated with CCK-8. It has been found that CDKN1A regulates DNA damage repair, which contributes to the improvement of osteoarthritis by regulating the pyroptosis of cartilage cells. However, the exact mechanistic effects are still unknown.","PeriodicalId":486374,"journal":{"name":"American journal of biomedicine","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140385362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Increased neutrophil-lymphocyte ratio in patients with COPD: case-control study","authors":"Nasser yousif","doi":"10.18081/2333-5106/2023.11/144","DOIUrl":"https://doi.org/10.18081/2333-5106/2023.11/144","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is one of the major causes of chronic morbidity and mortality and one of the major public health problems worldwide that affects millions of people all over the world. It is characterized by persistent airflow obstruction associated with enhanced inflammation in the airways and the lungs in response to noxious particles or gases. The main objective of this study is to investigate the neutrophil-lymphocyte ratio in patients with COPD as a case-control study. Between November 01, 2022, and February 28, 2023, patients were admitted to Al Hussain Teaching Hospital in Al Muthanna Governorate, Department of Medicine. The study included 51 patients with an approved diagnosis of COPD the mean age was 51.5 years, and 51 patients as control with other diseases mean age was 51.3 years). The subjects in all groups were 32 male and 19 female. Complete blood count (CBC) was measured from blood samples taken from patients. In the present study 51 COPD cases and 51 controls. No significant difference was observed between COPD cases and controls regarding age (p = 0.092); the average age of COPD cases was 51.5 years. No significant differences were observed between COPD cases and controls regarding gender (p = 0.085). At baseline, 21.0%, 40.3%, 25.7%, and 13% were diagnosed as COPD grade 1, 2, 3, and 4, respectively based on the (GOLD) classification. Baseline NLR significantly increased with the severity of COPD grade (1.3 vs. 2.7 vs. 2.2 vs. 2.9), p = 0.002). The cutoff for neutrophil-to-lymphocyte ratio, CRP, WBC, and ESR were 3.28, 2.32, 1.22, and 4.21 respectively. It has 85% sensitivity for detection of COPD exacerbation. and 89% specificity (AUC 0.798, p = 0.001). In conclusion, Blood NLR is a simple, inexpensive, widely available index that has been intensively evaluated in recent years in several clinical applications and in various diseases, including COPD.","PeriodicalId":486374,"journal":{"name":"American journal of biomedicine","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136278427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}